Company Name:Intersect ENT, Inc.
CEO: Thomas A. West

Sector: Health Technology

Exchange: NASDAQ

Country: US

Description: Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.

Key numbers

Market Capitalization:577925800
Shares Outstanding: 32559200
Float: 30946934
Next Earning Date:2020-08-04
TTm EPS: -1.5632
TTm Dividend Rate:
200 days moving average:17.97
50 days moving average: 14.17
One day percent Change: -4.48

2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,